Charles M Beasley

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
    Christopher D Carlson
    Eli Lilly and Company, Indianapolis, Ind, USA
    J Clin Psychiatry 64:898-906. 2003
  2. ncbi request reprint The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval
    Charles M Beasley
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Am Coll Cardiol 46:678-87. 2005
  3. doi request reprint Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings
    Charles M Beasley
    Lilly Corporate Center, Indianapolis, IN 46285, USA
    Expert Rev Clin Pharmacol 1:815-39. 2008
  4. doi request reprint Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Pacing Clin Electrophysiol 34:1116-27. 2011
  5. ncbi request reprint Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials
    Charles M Beasley
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    J Clin Psychopharmacol 27:682-6. 2007
  6. ncbi request reprint All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 27:252-8. 2007
  7. ncbi request reprint A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 1730, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 23:582-94. 2003
  8. ncbi request reprint Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients
    Stacy R Lindborg
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center DC 6324, 46285, Indianapolis, IN, USA
    Psychiatry Res 119:113-23. 2003
  9. ncbi request reprint Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:40-4. 2006
  10. ncbi request reprint Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder
    Sitra Tauscher-Wisniewski
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychol Med 37:1585-93. 2007

Collaborators

Detail Information

Publications25

  1. ncbi request reprint An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
    Christopher D Carlson
    Eli Lilly and Company, Indianapolis, Ind, USA
    J Clin Psychiatry 64:898-906. 2003
    ....
  2. ncbi request reprint The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval
    Charles M Beasley
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Am Coll Cardiol 46:678-87. 2005
    ..This study was designed to evaluate effects of tadalafil, a phosphodiesterase-5 inhibitor used for the treatment of erectile dysfunction (ED), on the QT interval...
  3. doi request reprint Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings
    Charles M Beasley
    Lilly Corporate Center, Indianapolis, IN 46285, USA
    Expert Rev Clin Pharmacol 1:815-39. 2008
    ..Design features and analytical methods that might be used in the thorough QT study to improve the chances of demonstrating the true relationship between a drug and QTc interval are reviewed. ..
  4. doi request reprint Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Pacing Clin Electrophysiol 34:1116-27. 2011
    ..However, little is known about systematic changes in the QTc across contiguous days when normal volunteers are brought into a controlled inpatient environment...
  5. ncbi request reprint Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials
    Charles M Beasley
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    J Clin Psychopharmacol 27:682-6. 2007
    ..05 vs placebo). Data sources were differentially sensitive in detecting changes in suicidal ideation and behaviors. Fluoxetine treatment led to greater benefit rather than risk for suicidality...
  6. ncbi request reprint All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 27:252-8. 2007
    ..This integrated analysis compared the likelihood of discontinuation from olanzapine treatment versus other antipsychotics among patients with schizophrenia...
  7. ncbi request reprint A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 1730, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 23:582-94. 2003
    ..In remitted stabilized patients with schizophrenia or schizoaffective disorder, olanzapine demonstrated a positive benefit-to-risk profile in relapse prevention...
  8. ncbi request reprint Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients
    Stacy R Lindborg
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center DC 6324, 46285, Indianapolis, IN, USA
    Psychiatry Res 119:113-23. 2003
    ..These data suggest that IM olanzapine has a favorable QTc interval profile in acutely agitated patients with schizophrenia, bipolar mania, or dementia...
  9. ncbi request reprint Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:40-4. 2006
    ....
  10. ncbi request reprint Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder
    Sitra Tauscher-Wisniewski
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychol Med 37:1585-93. 2007
    ....
  11. pmc Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers
    Corina Loghin
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Br J Clin Pharmacol 75:538-49. 2013
    ..The effects of atomoxetine (20 and 60 mg twice daily), 400 mg moxifloxacin and placebo on QT(c) in 131 healthy CYP2D6 poor metabolizer males were compared...
  12. ncbi request reprint Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials
    Ilya Lipkovich
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA
    Psychopharmacol Bull 42:23-39. 2009
    ..These results confirm that cut-offs for weight gain during the first 4 weeks of treatment may be useful in evaluating SWG risk for an individual patient...
  13. ncbi request reprint Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil
    R Dustan Sarazan
    Lilly Research Laboratories, Eli Lilly and Company, 2001 W Main St, Greenfield, Indianapolis, IN 46140, USA
    Eur J Pharmacol 502:163-7. 2004
    ..None of the three compounds was a potent blocker of the HERG channel...
  14. ncbi request reprint Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo
    Margaret O Sowell
    Lilly Research Laboratories, Eli Lilly and Co, Corporate Center, Drop Code 1758, Indianapolis, IN 46285, USA
    J Clin Endocrinol Metab 87:2918-23. 2002
    ..The results of this study do not support the hypothesis that olanzapine or risperidone directly impair pancreatic beta-cell function...
  15. ncbi request reprint Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia
    Karena M Meehan
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 26:494-504. 2002
    ..Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation...
  16. doi request reprint Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials
    Brian A Millen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Psychopharmacol 25:639-45. 2011
    ..Potential consequences of weight gain should be considered prior to starting olanzapine. Olanzapine-treated patients should receive regular weight monitoring...
  17. ncbi request reprint Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment
    David J Brunswick
    The Depression Research Unit, University of Pennsylvania Medical Center, University Science Center, 8th Floor, 3600 Market Street, Philadelphia, PA 19104, USA
    J Affect Disord 68:243-9. 2002
    ..The purpose of this study was to investigate the relationship between steady-state plasma drug concentrations and outcome during relapse-prevention therapy with fluoxetine...
  18. ncbi request reprint Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol
    Toshiya Inada
    National Center of Neurology and Psychiatry, Japan
    Int Clin Psychopharmacol 18:39-48. 2003
    ..This preliminary and retrospective work suggests that the DIEPSS can be used to operationally define the presence or absence, and make the clinical diagnosis, of specific EPS syndromes...
  19. ncbi request reprint Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications
    Cristina Cusin
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:52-7. 2007
    ..While patterns of response have been examined as possible predictors of outcome, the clinical correlates and implications of early worsening per se have not been investigated...
  20. ncbi request reprint Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes
    Roy H Perlis
    Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Psychother Psychosom 76:40-6. 2007
    ..The time course and clinical correlates of this phenomenon have not been characterized in detail...
  21. ncbi request reprint Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis
    William J Crumb
    Department of Pediatrics Cardiology, Tulane University School of Medicine, New Orleans, Lousiana, USA
    Pharm Res 23:1133-43. 2006
    ..To evaluate in vitro and computationally model the effects of selected antipsychotic drugs on several ionic currents that contribute to changes in the action potential in cardiac tissue...
  22. ncbi request reprint Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial
    Serge Carrier
    Department of Urology, Jewish General Hospital, 3755 Côte Sainte Catherine E 210, Montreal, Quebec, Canada H3T 1E2
    J Sex Med 2:685-98. 2005
    ..Erectile dysfunction (ED) is a highly prevalent, often undertreated condition...
  23. ncbi request reprint Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones
    Wayne J G Hellstrom
    Department of Urology SL 42, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    J Urol 170:887-91. 2003
    ..We assessed the effects on spermatogenesis of placebo vs 10 or 20 mg tadalafil administered daily for 6 months to healthy men and men with mild erectile dysfunction...
  24. ncbi request reprint Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial
    Jay M Young
    South Orange County Medical Research Center, 24301 Paseo de Valencia, Suite 100 Laguna Woods, CA 92653, USA
    J Androl 26:310-8. 2005
    ..The most common treatment-emergent adverse events were headache, back pain, dyspepsia, and nasopharyngitis. Both 10- and 20-mg tadalafil improved erectile function for up to 36 hours postdosing in men with ED of varied severity...
  25. ncbi request reprint A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil
    Alexander von Keitz
    Urology Practice, AM Krummbogen 15, 35039 Marburg, Germany
    Eur Urol 45:499-507; discussion 507-9. 2004
    ....